Abstract | STUDY OBJECTIVES: DESIGN: Prospective, but nonrandomized, study. SETTING: Cardiology division of an acute care hospital. PATIENTS: We studied 12 patients with third-degree intra-His or infra-His atrioventricular block who were in functional class II or III of the New York Heart Association classification. None of the patients had experienced Adams-Stokes attacks. INTERVENTIONS: These patients were given cilostazol orally at a dose of 200 mg daily for at least 1 week. MEASUREMENTS AND RESULTS: Before and after treatment with cilostazol, continuous 24-h ECG monitoring and measurement of plasma natriuretic peptide concentrations were performed. Cilostazol significantly increased the mean (+/- SEM) total 24-h QRS count from 57,300 +/- 2,800 to 74,400 +/- 3,200 beats (p = 0.001) and significantly decreased the maximum geometric mean R-R interval over a 24-h period from 1,900 ms (95% confidence interval [CI], 1,700 to 2,100 ms) to 1,600 ms (95% CI, 1,400 to 1,900 ms; p = 0.02), although none of the patients showed the abolishment of the atrioventricular conduction abnormalities. The total 24-h count of premature ventricular beats was not different before treatment (15 beats; 95% CI, 5 to 44 beats) and after treatment (12 beats; 95% CI, 5 to 30 beats; p = 0.57). Treatment with cilostazol significantly decreased the concentration of plasma atrial natriuretic peptide from 88 pg/mL (95% CI, 49 to 160 pg/mL) to 51 pg/mL (95% CI, 32 to 80 pg/mL; p = 0.007) and of brain natriuretic peptide from 166 pg/mL (95% CI, 71 to 389 pg/mL) to 77 pg/mL (95% CI, 30 to 178 pg/mL; p = 0.02). CONCLUSIONS:
|
Authors | Koji Kodama-Takahashi, Akira Kurata, Kiyotaka Ohshima, Kozo Yamamoto, Shigeki Uemura, Seiichiro Watanabe, Takeru Iwata |
Journal | Chest
(Chest)
Vol. 123
Issue 4
Pg. 1161-9
(Apr 2003)
ISSN: 0012-3692 [Print] United States |
PMID | 12684307
(Publication Type: Journal Article)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Tetrazoles
- Natriuretic Peptide, Brain
- Atrial Natriuretic Factor
- Cilostazol
|
Topics |
- Aged
- Aged, 80 and over
- Atrial Natriuretic Factor
(blood)
- Cilostazol
- Electrocardiography
- Female
- Heart Block
(blood, physiopathology, therapy)
- Heart Conduction System
(drug effects)
- Humans
- Male
- Middle Aged
- Natriuretic Peptide, Brain
(blood)
- Pacemaker, Artificial
- Platelet Aggregation Inhibitors
(pharmacology, therapeutic use)
- Prospective Studies
- Tetrazoles
(pharmacology, therapeutic use)
|